TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07392866: A Prospective, Randomized, Active-Controlled, Open-Label, National Multicenter Phase II/III Registration Study of SH006 Injection Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcino

Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07392866 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07392866 Rescue Dossier →